By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Mizuho today lowered estimates on Qiagen, citing concerns about competition, higher cost assumptions, and an unsettled European market.

Separately, the bank also downgraded diagnostic firm Alere, citing expected cost increases stemming from the firm's molecular diagnostics ambitions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.